Drug Type: Small Molecule
Mechanism Type: Improving muscle function
Mechanism: Tirasemtiv is a fast skeletal muscle troponin activator (FSTA) that increases the force of contraction by boosting the sensitivity of troponin to calcium.
U.S. Status for ALS: Discontinued
 VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Andrews, J. et al. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb 6:1-8. doi: 10.1080/21678421.2018.1426770.
 A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Shefner, JM et al. Amyotroph Lateral Scler Frontotemporal Degener. Jul-Aug;17(5-6):426-35.
 A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Shefner, JM et al. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81.
 Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS). ClinicalTrials.gov, 8 Mar 2016. Accessed 9 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02496767.
 Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. Hwee, DT. PLoS One. 2014 May 7;9(5):e96921.
Last updated February 8th, 2018